Global technology investor, Amadeus Capital Partners, announces the promotion of both Amelia Armour and Pierre Socha to Partner in the Early Stage Fund team.
Amelia Armour and Pierre Socha become Partners at Amadeus Capital Partners
Amelia commented: “I’m delighted to be recognised, having been supported by the great team at Amadeus over the past ten years. The most fulfilling part of the role is working with our portfolio companies to build global enterprises. I’m looking forward to working with many more ground-breaking startups across the UK.”
Pierre said: “Amadeus has been front and centre of deep technology investment for decades. I’m grateful to be given the opportunity to lead our early stage activities in biotech, medtech and digital health. We’re planning to grow our team and will keep pushing the boundaries in emerging tech investing.”
Amelia joined Amadeus in 2009. Her investment focus is on autonomous systems, AI and machine learning, cloud computing, digital health and medical technology. She is a Director on the boards of Sprout,ai, Xampla, Cambridge Touch Technologies, Paragraf, Immense Simulations, Baby2body, Riverlane and SLAMcore. Amelia is also a board observer at Prowler.io and Graphcore.
Pierre joined Amadeus in 2012 and manages early stage health and biotech investments for Amadeus. He is on the boards of Inotec, OriBiotech, Doctify, Congenica, PhoreMost, Quibim, and oversees our investments in Lumeon and Organox.
Amadeus Capital Partners is a global technology investor. Since 1997, the firm has raised over $1bn for investment and used it to back more than 130 companies. With vast experience and a great network, Amadeus’ team of investors and entrepreneurs share a passion for the transformative power of technology. We invest in consumer services, financial technology, artificial intelligence, cyber security, medical technology, digital healthcare and digital media.